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VaccinationObjectives: To describe and systematically review the modelling and reporting of cost-effectiveness anal-
ysis of vaccination in Hong Kong, and to identify areas for quality enhancement in future cost-
effectiveness analyses.
Methods: We conducted a comprehensive and systematic review of cost-effectiveness studies related to
vaccination and government immunisation programmes in Hong Kong published from 1990 to 2015,
through database search of Pubmed, Web of Science, Embase, and OVID Medline. Methodological quality
of selected studies was assessed using Consolidated Health Economic Evaluation Reporting Standards
checklist (CHEERS). Decision making of vaccination was obtained from Scientific Committee on
Vaccine Preventable Diseases (SCVPD) and Department of Health in Hong Kong.
Results: Nine eligible studies reporting twelve comparative cost-effectiveness comparisons of vaccination
programme for influenza (n = 2), pneumococcal disease (n = 3), influenza plus pneumococcal disease
(n = 1), chickenpox (n = 2), Haemophilus influenzae b (n = 1), hepatitis A (n = 1), cervical cancer (n = 1)
and rotavirus (n = 1) were identified. Ten comparisons (83.3%) calculated the incremental cost-
effectiveness ratio (ICER) of a vaccination strategy versus status quo as outcomes in terms of cost in
USD per life-years, cost per quality-adjusted life-years, or cost per disability-adjusted life-years.
Among those 10 comparisons in base-case scenario, 4 evaluated interventions were cost-saving relative
to status quo while the ICER estimates in 3 of the 6 remaining comparisons were far below commonly
accepted threshold and WHO willingness-to-pay threshold, suggestive of very cost-effective. Seven stud-
ies were of good quality based on the CHEERS checklist; one was of moderate quality; and one was of
excellent quality. The common methodological problems were characterisation of heterogeneity and
reporting of study parameters.
Conclusions: There was a paucity of cost-effectiveness models evaluating vaccination targeted to the
Hong Kong population. All evaluated vaccinations and immunisation interventions in Hong Kong, except
for Haemophilus influenzae b, hepatitis A and HPV vaccinations, were considered either cost-saving or
very cost-effective when compared to status quo.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3154
2. Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31552.1. Systematic literature search on cost-effectiveness models in Hong Kong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
2.1.1. Selection criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
2.1.2. Search engines and strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
2.1.3. Quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
2.1.4. Data extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155t, Ap Lei
3154 C.K.H. Wong et al. / Vaccine 35 (2017) 3153–31613. Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
4. Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3157
5. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3160
Funding source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3160
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3160
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3160
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31601. Introduction
In order to reduce the vaccine-preventable morbidity and mor-
tality, annual costs associated with national routine immunisation
programmes in low- and middle-income countries are going to
increase from US$3.5–4.5 billion in 2011 to US$50–80 billion in
2020 [1]. With scarce resources in public health care system, finan-
cial and budgetary impact are the major criteria of decision making
processes on which vaccine to introduce and sustain in national
immunisation programmes. Theoretically, resources allocated to
one emerging vaccine dedicated to one disease population may
displace the investment of another health intervention, irrespec-
tive of vaccination or not, potentially giving clinical benefits to
another disease population.
For equity in access to health services and resources allocation,
health economic evaluation including cost-effectiveness analysis
and cost-utility analysis is a widely-adopted methodology for
assessing the additional value of a new vaccine in current national
immunisation programmes. Conclusions from health economic
evaluation bring up important information to advisory body for
evidence-based recommendation, for example, National Immuni-
sation Technical Advisory Groups (NITAGs) in European countries
[2], The Advisory Committee on Immunisation Practices in the US
[3], and Australian Technical Advisory Group on Immunisation
(ATAGI) [4] in Australia. Apart from health economic evidence,
other essential factors such as disease burden, vaccine efficacy
and effectiveness, safety, feasibility of programme implementa-
tion, ethical and legal considerations also influence the decision
making from advisory body and health policy maker [5–8]. In the
UK where decision making process is heavily based on absolute
incremental cost-effectiveness ratio (ICER) threshold, the value of
vaccine for the gain in health of their populations is evaluated by
Joint Committee on Vaccination and Immunisation (JCVI) and com-
pared against country-specific threshold value to inform decision
making. Efficacious and effective vaccinations are more likely to
be incorporated into national immunisation programme in condi-
tion when health service is willing to pay for vaccine adoption to
routine practice.
In Hong Kong context, the Scientific Committee on Vaccine Pre-
ventable diseases, under the Centre for Health Protection [9], has
the responsibility of reviewing the up-to-date evidence from both
local data and overseas practice, and providing scientific advice
and recommendations on strategies for government immunisation
programmes in local population [9]. Three universal vaccination
programmes (Childhood Immunisation Programme, Government
Vaccination Programme, and Residential Care Home Vaccination
Programme) have been officially implemented by Department of
Health. Under Childhood Immunisation Programme, children have
been required to receive at least 12 injections before Primary Six
since February 2007 to prevent nine infectious diseases including
tuberculosis, poliomyelitis, hepatitis B, diphtheria, pertussis, teta-
nus, measles, mumps and rubella [10]. Since September 2009, four
doses of pneumococcal vaccine have been added to the vaccination
schedule for children aged two months, four months, six months
and 12 months, respectively. Varicella-containing vaccine for
prevention of chickenpox infection was recommended to bescheduled in Childhood Immunisation Programme since 2012,
and added to Childhood Immunisation Programme for infant since
June 2014 [11]. Completing the routine childhood immunisation
programme is a requirement for school entry in Hong Kong whilst
the coverage rates of these compulsory vaccines were over 99%
among Hong Kong-born children [11]. The decision making of
Childhood Immunisation Programme seems to follow the World
Health Organization’s recommendations [12] but excludes influen-
za, rotavirus and Haemophilus influenzae b (Hib) vaccines which
are available on the private market because of a hybrid public-
private healthcare system in Hong Kong [13]. The infant and
elderly were recommended to undertake 23-valent pneumococcal
polysaccharide vaccine since 2007. The 7-valent pneumococcal
conjugate vaccination (PCV-7) was incorporated in Childhood
Immunisation Programme for infant since 2007, and subsequently
replaced by pneumococcal polysaccharide vaccine with serotype
coverage, 10-valent (PCV-10) in 2010 and 13-valent (PCV-13) in
2011. Such changes in decision-making seem to be associated with
increasing availability of local epidemiological data, continuously
reviewing of vaccine safety and efficacy, and overseas experience
[9]. Both the trivalent and quadrivalent influenza vaccines for pre-
vention of seasonal flu were provided by public clinics and hospi-
tals under the Government Vaccination Programme and
Residential Care Home Vaccination Programme, and private doc-
tors under Vaccination Subsidy Scheme. However, the public
health objectives for the inclusion or exclusion of certain groups
for influenza vaccination prioritization are not clearly stated. Over-
all, group prioritization for influenza vaccination may be based on
risk of infection (e.g., young children and poultry workers), risk of
severe disease if infected (e.g., pregnant women) and risk of trans-
mission to other vulnerable people (e.g., healthcare workers, young
children, and elderly living in residential care homes) [14] with
data from surveys of public demands among the potential target
groups and may also take into account aspects of cost-benefit
and cost-effectiveness.
Although Hong Kong is considered as a region in high-income
counties, decision making process was calling for transparency to
the general public and health professional for critical appraisal
[15]. Recent systematic review [16] linking ICER values of evalu-
ated interventions to government’s decisions suggested that the
ICER values may be associated with advisory body’s decision to
inform recommendation. Nevertheless, the impact of cost-
effectiveness analysis of vaccination on decision making was
uncertain. A single ICER threshold value for decision making on
which vaccination to recommend and accept in public health care
system is not officially available in Hong Kong, besides the gross
domestic product per capita threshold recommended by World
Health Organisation [17].
Reporting standard, characteristics and assumption of cost-
effectiveness models evaluating vaccination influence the base-
case results, contributing to decision making on funding for
national immunisation programme. Following the World Health
Organisation guideline and consensus [18,19], critically appraisal
on whether methodology is properly analysed and adequately pre-
sented is a vital step before considering results and consequent
recommendations. Heterogeneity in modelling approaches and
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evaluating the same vaccination. Recent systematic reviews explic-
itly focused on the modelling aspects and results of cost-
effectiveness evaluation of vaccination in low- and middle-
income countries [22,23]. Results in a majority of studies consid-
ered the vaccination to be either cost-saving or very cost-effective.
The aims of this systematic review were (1) to review published
cost-effectiveness studies of vaccination in Hong Kong, and the
reporting quality of those studies, (2) identify areas for quality
enhancement of future cost-effectiveness studies, and (3) explore
whether cost-effective evidence of vaccination was associated with
decisions making about the recommendation and acceptance of a
particular vaccination into government immunisation programmes
in Hong Kong.2. Method
2.1. Systematic literature search on cost-effectiveness models in Hong
Kong
2.1.1. Selection criteria
The eligibility criterion of studies was to evaluate the cost-
effectiveness of vaccination and immunisation interventions
against the status quo (i.e. existing vaccination policy and clinical
practice) as the comparator. Articles without available full text or
full report were excluded. If there were duplicated articles or
reports, the most complete work done by authors was selected.
After the initial check for duplicated articles, the abstracts of
remaining articles were screened by authors (CW and VG) to
exclude editorials, letters, commentaries, study protocols, case
reports, pure literature reviews and meta-analyses, conference
proceedings, past and current clinical guidelines, and
recommendations.
2.1.2. Search engines and strategies
A systematic and comprehensive literature search was con-
ducted in databases of PubMed, Web of Science using the Web of
Knowledge platform, Embase, and MEDLINE using the Ovid search-
ing platform to identify studies that investigated the economic
evaluation of health interventions to be considered in public clin-
ical setting in Hong Kong. The Medical Subject Heading ‘‘Hong
Kong”, ‘‘China”, and ‘‘Chinese” were combined with ‘‘cost-effectiv
eness”, ‘‘cost-effective”, ‘‘cost-benefit”, ‘‘cost-utility”, ‘‘cost-mini
mization”, ‘‘cost-minimisation”, ‘‘cost-saving”, ‘‘willingness-to-pa
y” and ‘‘economic evaluation”. Studies were limited to English lan-
guage and the publication years between 1990 and 2015. The ear-
liest year was chosen as 1990 because the concept of value for
money in health emerged around early-1990s [24]. Such searching
strategies were adopted from a previous literature review [16] on
the health technology assessment of cancer screening strategies
in Hong Kong. All searches were performed within the University
of Hong Kong during March 2015.
2.1.3. Quality assessment
Methodological quality of the included studies was assessed
according to the Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) checklist [25], which was adopted as the
evaluation of reporting standard of health economics analysis.
The CHEERS checklist contains 24 criteria assessing different
aspects of quality and reporting standard of economic evaluations:
background and objectives, target population and subgroups, set-
ting and location, study perspective, comparators, time horizon,
discount rate, choice of health outcomes, measurement of
effectiveness, measurement and valuation of preference based
outcomes, estimating resources and costs, choice of model,assumptions, analytical methods, study parameters, incremental
costs and outcomes, characterising uncertainty, characterising
heterogeneity, study findings, limitations, generalisability, source
of funding, and conflicts of interest. For each included study, each
reporting quality criterion was rated as ‘‘yes” with a score of 1 or
‘‘no” with a score of 0 to indicate if the quality criterion was met
or not for each criterion, respectively. Furthermore, overall quality
rating of included studies was scored on a four-point Likert scale in
a descending order of ‘‘excellent”, ‘‘good”, moderate” or ‘‘low” qual-
ity when study fulfilled 100%, >75–<100%, >50–75%, or 50% of
the criteria, respectively. Articles with ‘‘low” reporting standard
that lack transparency and clarity were further excluded from sub-
sequent analyses. This classification has been used in previous sys-
tematic reviews of health economic evaluations [26,27].2.1.4. Data extraction
A standardized form was used when extracting the data
reported in included studies. The primary data extracted from each
article involved: first authorship, year of publication, design or
type of economic evaluation, targeted disease (influenza, pneumo-
coccal disease, chickenpox, Hib, hepatitis A, cervical cancer and
rotavirus), targeted population (infant aged < 1, children aged 1–
17, elderly aged 65 or above, girls aged 10–17, and general popula-
tion), comparator, study perspective, year cost, price of vaccine,
clinical data source, modelling approaches, sensitivity analysis per-
formed, and cost-effectiveness outcomes. Modelling characteristics
included type of models (Markov model, decision tree, discrete-
event simulation, dynamic model or no models), time horizons,
discount rate, preference valuation, and sensitivity analysis. Each
health economic assessment of vaccination strategy versus the
comparator was defined as one comparative cost-effectiveness
analysis. For each pairwise cost-effectiveness comparison, we
obtained the ICER value at base-case scenario, as expressed in cost
per event cases prevented, cost (USD) per life years gained, cost per
QALYs gained, or cost per disability-adjusted life years (DALYs)
averted of one vaccination strategy relative to the comparator.
Conclusion of included studies was grounded on the ICER value
at base-case scenario. Costs in each strategy and ICER value for
each pairwise cost-effectiveness comparison were not adjusted
for year of valuation.3. Results
Fig. 1 lists the process of literature identification, abstract
screening for eligibility, and selection of original studies during
the literature and hand search presented in a Preferred Reporting
Items for Systematic Reviews and meta-Analyses flow diagram
[28]. Systematic database search identified 1335 potentially rele-
vant studies (PubMed: 446; Web of Science: 232; MEDLINE: 300;
and Embase: 357) that met the searching criteria in four research
databases. After the removal of duplicated (n = 544) and non-
original articles (n = 237) by abstract screening, the full-text of
70 studies were assessed for eligibility. Among them, 62 were
not related to vaccination and one did not focus on cost-
effectiveness analysis of vaccination [29]. Based on bibliographic
database search, seven cost-effectiveness analyses related to vacci-
nation in Hong Kong were included. A total of nine studies, seven
from bibliographic databases and two from hand searches, was
finally included in this systematic review. The earliest study was
published in year 2001.
Table 1 summarizes description and modelling characteristics
of included studies. Nine eligible studies reporting twelve compar-
ative cost-effectiveness comparisons of vaccination and immunisa-
tion programme for influenza (n = 2), pneumococcal disease
(n = 3), influenza plus pneumococcal disease (n = 1), chickenpox
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3156 C.K.H. Wong et al. / Vaccine 35 (2017) 3153–3161(n = 2), Hib (n = 1), hepatitis A (n = 1), cervical cancer (n = 1) and
rotavirus (n = 1) were identified. No vaccinations except for chick-
enpox, influenza, and pneumococcal disease, were implemented in
government immunisation programme. Two-third (n = 6) of stud-
ies disclosed no funding or non-industry funding. Most studies
established a Markov model (33.3%), evaluated from the perspec-
tive of health care provider (33.3%) or societal (33.3%), reported
an ICER of vaccination strategy versus the comparator in effective-
ness unit of QALY only (55.6%), applied an annual discount rate of
3.0% (55.6%), performed probabilistic sensitivity analysis (55.6%),
and adopted list price or acquisition price of vaccine (55.6%). Time
horizon applied in modelling varied between studies.
Evaluated vaccination, comparators, target disease population
and main results of studies are found in Table 2. Evaluated vaccina-
tions included varicella vaccine, influenza programme particularly
for quadrivalent influenza and trivalent influenza, pneumococcal
vaccine for 7-valent, 10-valent and 13-valent conjugates, rotavirus,human papillomavirus vaccination (HPV) and combined vaccines
for the Hib, chickenpox, pneumococcal, and hepatitis A. Pneumo-
coccal vaccinations were evaluated in infant and elderly. Two
cost-effectiveness comparisons reported the ‘influenza-like illness
case prevented’ [30] or ‘Benefit-to-cost ratio’ [31] as the only effec-
tiveness unit, in which health economic outcome was not
expressed as ICER value to compare against ICER threshold for rec-
ommendation. Out of the remaining ten comparisons, four com-
parisons demonstrated a negative ICER value as a result of cost-
saving [32–35] and six comparisons reported ICER values from
USD500 to USD3,525,635 where available [36,37]. Particularly for
those studies reporting positive ICER values, the universal PCV-7
vaccination targeting to infant pneumococcal disease was regarded
as cost-effective with an ICER value of USD6460 per life year
gained while the influenza and pneumococcal vaccination target-
ing to elderly subjects was also considered as cost-effective with
an ICER value of USD500 per QALY gained. The ICER values of
Table 1
Description and modelling characteristics of nine included studies.
n (%) n (%)
Year of publication Reporting of ICER
2000–2005 1 (11.1) LY only 1 (11.1)
2006–2010 4 (44.4) QALY only 5 (55.6)
2011–2015 4 (44.4) LY & QALY 1 (11.1)
Funding source Others or not reported 2 (22.2)
Industry 1 (11.1) Model type
Non-industry 3 (33.3) Decision Tree 2 (22.2)
No funding 3 (33.3) Decision-analytic model 1 (11.1)
Non-disclosed 2 (22.2) Markov model 3 (33.3)
Types of economic evaluation Epidemiology model 1 (11.1)
Cost-utility 6 (66.7) Markov & dynamic model 2 (22.2)
Cost-effectiveness 3 (33.3) Time horizon
Disease population 80-year 1 (11.1)
Chickenpox 1 (11.1) 50-year 1 (11.1)
Influenza 2 (22.2) 10-year 2 (22.2)
Pneumococcal disease 2 (22.2) 9-year 1 (11.1)
Influenza & pneumococcal disease 1 (11.1) 5-year 2 (22.2)
Rotavirus 1 (11.1) Not reported 2 (22.2)
Hib, chickenpox, pneumococcal & hepatitis A 1 (11.1) Year cost
Cervical cancer 1 (11.1) 2001–2005 1 (11.1)
Target population 2006–2010 3 (33.3)
Infant 4 (44.4) 2011–2015 2 (22.2)
Elderly (65 years) 2 (22.2) Not reported 3 (33.3)
Pediatric 1 (11.1) Annual discount rate
Girls (10–17y) 1 (11.1) 0.0% 1 (11.1)
Elderly (65–80 yr), Children (1–15 yr) & Working age 1 (11.1) 3.0% 5 (55.6)
Study Perspective 5.0% 2 (22.2)
Healthcare provider 3 (33.3) Not reported 1 (11.1)
Societal 3 (33.3) Preference or utility valuation
Payer 1 (11.1) By assumption 6 (66.7)
Payer & societal 1 (11.1) No calculation of QALY 3 (33.3)
Healthcare provider & societal 1 (11.1) Sensitivity analysis
Price of Vaccine Deterministic 3 (33.3)
List or acquisition price 5 (55.6) Probabilistic 5 (55.6)
Not reported 4 (44.4) No 1 (11.1)
Note: Hib = Haemophilus influenzae b; ICER = Incremental cost-effectiveness ratios; LY = life-year; QALY = quality-adjusted life-year.
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infant were USD7564, USD20,725, and USD3,525,635 per life year
gained, respectively [31]. Adding HPV vaccination for 12-year old
girls had an ICER value of USD11,732-USD14,202 per QALY gained
[38]. All evaluated vaccinations, except for HPV, Hib and hepatitis
A [31] vaccinations, were considered either cost-saving or very
cost-effective based on conclusions of included studies in Hong
Kong. Those cost-effective or recommended vaccinations, except
for one evaluating the universal rotavirus vaccination for infant
[33], was included in government immunisation programme.
Therefore, cost-effective evidence from published studies and
reports appeared to be associated with decision-making from
government.
Table 3 shows the reporting quality of each study represented
by the scoring of the CHEERS checklist. Seven studies were of good
quality based on the CHEERS checklist [31–37], one was of moder-
ate quality [30], one was of excellent [38], and none was of low. In
summary, 19 out of the 24 items were fulfilled by >80% of the stud-
ies except in the items of time horizon (item 8), study parameters
(item 18), characterising heterogeneity (item 21), source of fund-
ing (item 23) and conflicts of interest (item 24). In particular,
two studies met the quality criteria of characterising heterogene-
ity, and explained variations in cost, outcomes or cost-
effectiveness between subgroups. Two [30,32] of the nine studies
did not mention the time horizon over which costs and conse-
quences were being evaluated. Two studies [30,33] did not
describe any potential for conflicts of interest of study contribu-
tors. Two studies [35,36] did not clearly state the funding sources,
denoted as ‘non-disclosure’, while one study [34] out of seven
remaining studies declared the support from industry-sponsorship. Three studies [30,34,37] did not state the study
parameters like values, ranges, references and probability distribu-
tions for all parameters.4. Discussions
This systematic review synthesized the cost-effective evidence
and appraised the reporting quality of published cost-
effectiveness analysis of vaccination in Hong Kong. The principal
findings based on published evidence was that all evaluated vacci-
nation and immunisation interventions, except for Hib, hepatitis A
and HPV vaccinations, were considered either cost-saving or very
cost-effective when compared to status quo, in line with health
economic evidence reported in previous systematic reviews
[21,23]. Evidence from this review did not draw conclusion on
whether the ICER values were associated with decision-making
of government to recommend and implement the vaccination
and immunisation programme in Hong Kong. Interestingly, all
cost-effective or recommended vaccinations except for universal
rotavirus vaccination were included in government immunisation
programme. Despite that universal rotavirus vaccination was con-
sidered as cost-saving strategy in the literature, rotavirus vaccine is
neither been recommended by SCVPD [9] nor included in Hong
Kong Childhood immunisation programme for implementation
[11]. To an extent, the ICER values of four cost-effectiveness com-
parisons were not available [32–35], due to dominance or cost-
saving. Merely one out of four dominated vaccinations was neither
recommended nor implemented; leading to the notion that cost-
effective evidence may be associated with the recommendation
Table 2
Evaluated vaccinations, comparators, target disease and population, and main results of nine studies.
First
author
Year Funding source Design / type
of econ-
evaluation
Target disease Intervention Comparators
of
intervention
Target
population
Study
Perspective
Source of
clinical data
Chui 2014 No funding Cost-utility Chickenpox Varicella vaccine as post-
exposure prophylaxis
No
vaccination
Pediatric
(1-18y)
Healthcare
provider
Local cohort
data and
overseas
literature
Fitzner 2001 No funding Cost-
effectiveness
Influenza Influenza prevention
programme
No
vaccination
Elderly
(65-80y)
Children
(1-15y)
Working-
age
Societal Local
surveillance and
cohort data
Ho 2008 Non-industry Cost-
effectiveness
Rotavirus Universal rotavirus
vaccination
No
vaccination
Infant Healthcare
provider
Local cohort
data and
overseas
literature
Lee 2009 Non-disclosed Cost-
effectiveness
Pneumococcal
disease
Universal PCV-7
vaccination
No
vaccination
Infant Payer &
societal
Local cohort
data and
overseas
literature
Lee 2013 Industry Cost-utility Pneumococcal
disease
Universal PCV-10
vaccination versus
universal PCV-13
vaccination
Universal
PCV-13
vaccination
Infant Payer Local literature
only
You 2009 Non-disclosed Cost-utility Influenza and
pneumococcal
disease
Influenza and
pneumococcal vaccination
No
vaccination
Elderly
(65 y)
Healthcare
provider
Local cohort
data and
overseas
literature
You 2014 No funding Cost-utility Influenza Quadrivalent influenza
vaccine versus trivalent
influenza vaccine
Trivalent
influenza
vaccine
Elderly
(65 y)
Societal Local cohort
data and
overseas
literature
McGhee 2008 Non-industry
(commissioned by
government)
Cost-utility Hib, chickenpox,
pneumococcal,
hepatitis a
Combined vaccines for the
Hib, chickenpox,
pneumococcal, and
hepatitis A
No
vaccination
Infant Healthcare
provider &
societal
Local cohort
data and
overseas
literature
Wu 2012 Non-industry
(commissioned by
government)
Cost-utility Cervical cancer Human papillomavirus
vaccination
No
vaccination
Girls
(10–17 y)
Societal Local
surveillance and
cohort data
First
author
Year Reporting of cost-effectiveness
outcomes
Conclusions Type of Model Time
horizon
Year
cost
Price of
vaccine
Discount
rate
Sensitivity
analysis
ICER LY QALY Others
Chui 2014 Yes No Yes No Varicella vaccine as post-exposure
prophylaxis was cost-saving
Decision tree NR NR List
price
0% Probabilistic
Fitzner 2001 No No No Influenza-
like
illness
case
prevented
Influenza vaccine was cost-effective
from the perspective of a susceptible
Individual but not from societal
perspective
Decision tree NR NR List
price
NR Deterministic
Ho 2008 Yes No No DALY
averted
A universal rotavirus vaccination
was cost-saving
Markov
model
5-year 2002 NR 3% Probabilistic
Lee 2009 Yes Yes No IPD
prevented
Routine infant vaccination with
PCV-7 was cost-effective
Decision-
analytic
model
10-year 2006 NR 5% Deterministic
Lee 2013 Yes No Yes IPD
prevented
PCV-10 vaccination was a cost-
saving strategy compared with PCV-
13 vaccination
Markov
model
10-year 2011 NR 5% Probabilistic
You 2009 Yes No Yes No Influenza vaccination with or
without pneumococcal vaccination
was cost-saving
Markov
model
5-year 2006 List
price
3% Probabilistic
You 2014 Yes No Yes No Quadrivalent influenza vaccine was
cost-effective
Epidemiology
model
9-year 2014 NR 3% No
McGhee 2008 Yes Yes Yes Benefit-
to-cost
ratio
Pneumococcal vaccine showed more
benefit than costs. Hib vaccine was
cost-effective given using a very
conservative model. Varicella and
hepatitis A vaccines had
uncertainties on cost-effectiveness
Markov
model and
dynamic
model (for
Varicella)
80-year NR List
price
3% Deterministic
Wu 2012 Yes No Yes No HPV vaccination of 12-year-old girls
was a cost-effective addition to
current cervical cancer prevention
guidelines
Markov
model and
dynamic
model
50-year 2010 List
price
3% Probabilistic
Note: ICER = incremental cost-effectiveness ratio; LY = life-years; QALY = quality-adjusted life-years; DALY = disability-adjusted life-years; IPD = invasive pneumococcal
disease; Hib = Haemophilus influenzae b; HPV = human papillomavirus; NR = not reported.
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Table 3
Reporting standards of nine included health economic evaluation studies.
First author Chui Fitzner Ho Lee Lee You You McGhee Wu Total
Publication year 2014 2001 2008 2009 2013 2009 2014 2008 2012 % of Yes
CHEERS statement item number
1 Title 1 1 1 1 1 1 1 1 1 100%
2 Abstract 1 1 1 1 1 1 1 1 1 100%
3 Background and objectives 1 1 1 1 1 1 1 1 1 100%
4 Target population and subgroups 1 1 1 1 1 1 1 1 1 100%
5 Setting and location 1 1 1 1 1 1 1 1 1 100%
6 Study perspective 1 1 1 1 1 1 1 1 1 100%
7 Comparators 1 1 1 1 1 1 1 1 1 100%
8 Time horizon 0 0 1 1 1 1 1 1 1 78%
9 Discount rate 1 0 1 1 1 1 1 1 1 89%
10 Choice of health outcomes 1 1 1 1 1 1 1 1 1 100%
11 Measurement of effectiveness 1 1 1 1 1 1 1 1 1 100%
12 Measurement and valuation of preference based outcomes 1 0 1 1 1 1 1 1 1 89%
13 Estimating resources and costs 1 1 1 1 1 1 1 1 1 100%
14 Currency, price date, and conversion 1 0 1 1 1 1 1 1 1 89%
15 Choice of model 1 1 1 1 1 1 0 1 1 89%
16 Assumptions 1 1 1 1 1 1 1 1 1 100%
17 Analytical methods 1 1 1 1 1 1 0 1 1 89%
18 Study parameters 1 0 1 1 0 1 0 1 1 67%
19 Incremental costs and outcomes 1 1 1 1 1 1 1 1 1 100%
20 Characterising uncertainty 1 1 1 1 1 1 0 1 1 89%
21 Characterising heterogeneity 0 1 0 0 0 0 0 0 1 22%
22 Study findings, limitations, generalizability, and current knowledge 1 1 1 1 1 1 1 1 1 100%
23 Source of funding 1 1 1 0 1 0 1 1 1 78%
24 Conflicts of interest 1 0 0 1 1 1 1 1 1 78%
% of Yes 92% 75% 92% 92% 92% 92% 79% 96% 100%
Overall quality Good Moderate Good Good Good Good Good Good Excellent 90%
Note: ‘‘1” Meets the quality assessment criteria, ‘‘0” does not fully conform to the quality assessment criteria.
CHEERS - Consolidated Health Economic Evaluation Reporting Standards.
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addition to cost-effective evidence, other practical considerations
such as disease prevalence, vaccine efficacy, budgetary constraints
and public acceptance were also taken into account when making
recommendation and funding decision by government.
The use of CHEERS checklist allows consistent and fair compar-
isons of quality reporting across studies. Overall reporting quality
was good when appraising the quality assessment criteria outlined
in CHEERS checklist and one of the studies was rated as excellent in
overall quality. Reporting quality of studies was gradually
improved from ‘moderate’ to ‘good’ or ‘excellent’ quality standard
over the years. In order to achieve the ‘excellent’ quality standard,
subgroup analysis which reports variability across subgroups
should be conducted in future health economic evaluations.
Most studies utilized the local real-world cohort data and over-
seas literature as source of clinical data but the clinical data source
of remaining three studies [30,34,38] was primarily based on
assumption and local data only. This was in part due to the lack
of epidemiological cohort data to estimate the natural history of
disease progression and burden, and randomized controlled trial
data to estimate the adverse effects and efficiency of vaccine in
Hong Kong. Moreover, most studies adopted the acquisition costs
or market prices as the price of vaccine but the type of vaccine
price was unstated for the remaining studies. Varying the amount
of vaccine price had impact on results of cost-effectiveness analy-
sis. With the demand for the transparency of vaccine price, WHO
has set out a comprehensive web platform [39] which provides
information on average vaccine price for countries of all income
groupings.
With respect to methodological and modelling aspects, health
economic outcomes were mostly modelled by static modelling like
Markov models and decision trees. By principle, model type has to
be adequately chosen depending upon targeted disease population
[40]. Future models simulating health economic impact of
vaccinations for infectious diseases, e.g. seasonal influenza, human
papillomavirus and chickenpox, should be established usingtransmission dynamic modelling approach accounting for direct
benefit of prevention of disease transmission between individuals
within the community due to vaccination, indirect benefit of herd
immunity effects, and the change in parameter values over time
[20]. This review identified two studies [31,32] applying different
modelling approaches to evaluate the cost-effectiveness of varicella
vaccine. Chui et al. [32] applying the static modelling approach
expressed the health benefits in QALY whilst the earlier report
[31] establishing dynamic modelling demonstrated benefit-to-
cost ratio for such cost-effectiveness comparison. Hence, compar-
isons in results between static and dynamic models are warranted.
Role of industry-sponsorship may lead to a publication bias
which was in favour of vaccine products developed by sponsors,
as recognized in systematic review of economic evaluations on
pneumococcal vaccines conducted in European countries [41].
Conclusion of one industry-sponsored study [34] reported that
the universal PCV-10 vaccination targeting to infant pneumococcal
disease was dominant strategy relative to universal PCV-13 vacci-
nation. Nevertheless, one recent industry-sponsored study [42],
out of the scope of searching period, found universal PCV-13 vacci-
nation was a better option than PCV-10 vaccination and no vacci-
nation, contradictory to previous modelling study with PCV-10 in
comparison to PCV-13 vaccination [34]. Researchers are urged
interpreting findings of industry-sponsored studies with caution.
Among two studies which were not disclosed with any funding
[35,36], conclusions were considered evaluated vaccination as
cost-effective. For those indicating either no funding or non-
industry funding, evaluated vaccination was dominant strategy.
Collectively, influence of industry-sponsorship on conclusion was
not evident in this review, calling for more cost-effectiveness anal-
yses to ascertain whether the sponsorship effect did exist or not.
On one hand, recommendations from studies [31,38] commis-
sioned by government heavily influenced the decision making of
whether the vaccine is included in government immunisation
programme. In the commissioned study published in 2008 [31],
pneumococcal vaccine was recommended to be included in
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rated PCV-7 vaccination in 2009 [11]. Besides the funding source,
there was a paucity of published cost-effectiveness models evalu-
ating meningococcal, Japanese encephalitis and herpes zoster vac-
cinations targeted to Hong Kong population. As such, we urged
further research in heath economic evaluations of emerging vacci-
nations, if applicable to Hong Kong setting.
Systematic reviews of vaccinations in a low- and middle-
income countries context highlighted the variability of the ICER
threshold used for different studies in the same country [22], and
hence emphasized the need for ICER threshold value for decision
making [43]. However, estimation of willing to pay for vaccination
and an ICER threshold value of vaccination adoption decision mak-
ing in Hong Kong as high-income country was not possible, in con-
trast to previous pooled analyses revealing that the increase in
ICER value was associated with a lower likelihood of positive past
decision [44,45].
5. Conclusions
There was a paucity of cost-effectiveness models evaluating
vaccination targeted to Hong Kong population. All evaluated vacci-
nations and immunisation interventions in Hong Kong, except for
Hib, hepatitis A and HPV vaccinations, were considered either
cost-saving or very cost-effective when compared to status quo,
based on findings reported from included studies. Cost-effective
evidence may be associated with the recommendation and imple-
mentation of vaccination in Hong Kong. Future studies evaluating
the cost-effectiveness of vaccination in Hong Kong should improve
the reporting quality, especially list of study parameters, and con-
duct subgroup analysis and dynamic modelling for simulation.
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